Details
Tesamorelin
CAS 218949-48-5
2mg/vial
Purity: 99%
Specification: 2mg/vial
Appearance: White Lyophilized Powder
Place of Origin: China
Standard: USP
Certification: SGS
Method of Analysis: HPLC
Storage: Lyophilized peptides although stable at room temperature for 3 months, should be stored desiccated below -18° C. Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18° C.
Description:
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
Tesamorelin (also known as Egrifta) is a synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.
p;tendon fibroblasts in a dose-dependent manner as revealed by transwell filter migration assay. BPC 157 also dose dependently accelerated the spreading of tendon fibroblasts on culture dishes. The F-actin formation as detected by FITC-phalloidin staining was induced in BPC 157-treated fibroblasts. The protein expression and activation of FAK and paxillin were determined by Western blot analysis, and the phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157 while the total amounts of protein was unaltered. In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.
use:Triptorelin raises testosterone levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
Applications:
LH and FSH concentrations in heifers were monitored after intramuscular applications of fertirelin acetate and GnRH products including gonadorelin acetate.
Each heifer was exposed to nine applications of each chemical for 8-16 day cycles. Groups were exposed to buserelin, gonadorelin acetate or fertirelin acetate.
After these applications blood samples were drawn 1-8 hours later to log the responses to these chemicals and the different reactions between them.
After plotting this data it was determined that a plateau could be reached applying fertirelin acetate more quickly than the other chemical bodies.
China (Mainland)